Connect Biopharma (CNTB) News Today $0.78 +0.03 (+3.82%) Closing price 05/28/2025 03:59 PM EasternExtended Trading$0.80 +0.02 (+2.06%) As of 07:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTB Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Connect Biopharma (NASDAQ:CNTB) Stock Price Up 3.8% - Here's What HappenedMay 29 at 2:54 AM | americanbankingnews.comConnect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International ConferenceMay 20, 2025 | globenewswire.comConnect Biopharma Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | globenewswire.comConnect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPDMay 14, 2025 | globenewswire.comConnect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in AsthmaMay 13, 2025 | globenewswire.comConnect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International ConferenceApril 24, 2025 | globenewswire.comBullfrog AI and Connect Biopharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVApril 11, 2025 | markets.businessinsider.comConnect Biopharma announces feedback from FDA Type C meeting for RademikibartApril 2, 2025 | markets.businessinsider.comConnect Biopharma publishes results from rademikibart trialApril 1, 2025 | markets.businessinsider.comConnect Biopharma Announces Positive Type C Meeting with the FDA for RademikibartApril 1, 2025 | globenewswire.comConnect Biopharma reports FY24 (28c) vs ($1.13) last yearMarch 31, 2025 | markets.businessinsider.comConnect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled AsthmaMarch 31, 2025 | globenewswire.comConnect Biopharma Reports 2024 Full-Year Financial Results and Provides Business UpdateMarch 31, 2025 | globenewswire.comConnect Biopharma faces Nasdaq delisting over share priceMarch 30, 2025 | uk.investing.comConnect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementMarch 28, 2025 | globenewswire.comConnect Biopharma to Present at Two Upcoming Investor ConferencesMarch 3, 2025 | globenewswire.comConnect Biopharma Holdings And Two Other Promising Penny Stocks To WatchFebruary 28, 2025 | finance.yahoo.comBrokers Offer Predictions for CNTB FY2024 EarningsConnect Biopharma Holdings Limited (NASDAQ:CNTB - Free Report) - Equities researchers at Leerink Partnrs issued their FY2024 earnings per share (EPS) estimates for Connect Biopharma in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith fFebruary 10, 2025 | marketbeat.comFY2029 Earnings Estimate for CNTB Issued By Leerink PartnrsConnect Biopharma Holdings Limited (NASDAQ:CNTB - Free Report) - Investment analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for shares of Connect Biopharma in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith anticipates that thFebruary 7, 2025 | marketbeat.comConnect Biopharma (NASDAQ:CNTB) Shares Down 0.8% - Should You Sell?Connect Biopharma (NASDAQ:CNTB) Shares Down 0.8% - Time to Sell?January 21, 2025 | marketbeat.comConnect Biopharma Holdings Limited (NASDAQ:CNTB) Short Interest Up 53.5% in DecemberConnect Biopharma Holdings Limited (NASDAQ:CNTB - Get Free Report) was the recipient of a large growth in short interest in December. As of December 15th, there was short interest totalling 87,800 shares, a growth of 53.5% from the November 30th total of 57,200 shares. Based on an average daily trading volume, of 28,200 shares, the days-to-cover ratio is presently 3.1 days. Approximately 0.2% of the shares of the stock are sold short.December 28, 2024 | marketbeat.comConnect Biopharma Appoints New Accounting FirmDecember 23, 2024 | tipranks.comConnect Biopharma Holdings Limited (NASDAQ:CNTB) Short Interest Down 7.4% in NovemberConnect Biopharma Holdings Limited (NASDAQ:CNTB - Get Free Report) was the recipient of a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 57,200 shares, a decrease of 7.4% from the November 15th total of 61,800 shares. Based on an average daily trading volume, of 26,600 shares, the days-to-cover ratio is presently 2.2 days. Currently, 0.1% of the company's stock are short sold.December 16, 2024 | marketbeat.comConnect Biopharma Hldgs (NASDAQ:CNTB) Stock, Option ChainNovember 14, 2024 | benzinga.comShort Interest in Connect Biopharma Holdings Limited (NASDAQ:CNTB) Increases By 26.7%Connect Biopharma Holdings Limited (NASDAQ:CNTB - Get Free Report) was the recipient of a large increase in short interest in the month of October. As of October 15th, there was short interest totalling 45,500 shares, an increase of 26.7% from the September 30th total of 35,900 shares. Based on an average daily volume of 27,300 shares, the short-interest ratio is presently 1.7 days. Currently, 0.1% of the shares of the company are sold short.October 30, 2024 | marketbeat.comAttovia Therapeutics Appoints Chief Financial OfficerOctober 15, 2024 | globenewswire.comCNTB Stock Surges Over 5% Amid Strong Financial PerformanceOctober 2, 2024 | gurufocus.comConnect Biopharma Holdings Limited (NASDAQ:CNTB) Sees Large Growth in Short InterestConnect Biopharma Holdings Limited (NASDAQ:CNTB - Get Free Report) was the recipient of a large increase in short interest in September. As of September 15th, there was short interest totalling 22,400 shares, an increase of 5.2% from the August 31st total of 21,300 shares. Approximately 0.0% of the company's stock are sold short. Based on an average trading volume of 42,600 shares, the short-interest ratio is currently 0.5 days.October 1, 2024 | marketbeat.comCentessa Pharmaceuticals: Progressing SerpinPC Through Registrational Trials In Hemophilia BSeptember 25, 2024 | seekingalpha.comSimcere Pharmaceutical Group Ltd (S2P.DU)September 25, 2024 | sg.finance.yahoo.comConnect Biopharma Holdings Limited (NASDAQ:CNTB) Short Interest Up 76.0% in AugustConnect Biopharma Holdings Limited (NASDAQ:CNTB - Get Free Report) was the recipient of a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 21,300 shares, an increase of 76.0% from the August 15th total of 12,100 shares. Based on an average trading volume of 50,600 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.0% of the company's shares are sold short.September 13, 2024 | marketbeat.comConnect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024September 10, 2024 | finance.yahoo.comHC Wainwright Reaffirms "Buy" Rating for Connect Biopharma (NASDAQ:CNTB)HC Wainwright restated a "buy" rating and issued a $8.00 target price on shares of Connect Biopharma in a research note on Friday.September 6, 2024 | marketbeat.comConnect Biopharma Reports First Half 2024 Financial Results and Provides Business UpdateSeptember 5, 2024 | globenewswire.comShort Interest in Connect Biopharma Holdings Limited (NASDAQ:CNTB) Decreases By 9.7%Connect Biopharma Holdings Limited (NASDAQ:CNTB - Get Free Report) was the recipient of a large decrease in short interest during the month of August. As of August 15th, there was short interest totalling 12,100 shares, a decrease of 9.7% from the July 31st total of 13,400 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 48,900 shares, the short-interest ratio is presently 0.2 days.September 1, 2024 | marketbeat.comConnect Biopharma Holdings (NASDAQ:CNTB) Is In A Good Position To Deliver On Growth PlansAugust 29, 2024 | finance.yahoo.comConnect Biopharma Holdings Limited Share ChatAugust 25, 2024 | lse.co.ukConnect Biopharma Holdings Limited (NASDAQ:CNTB) Short Interest Down 44.2% in JuneConnect Biopharma Holdings Limited (NASDAQ:CNTB - Get Free Report) was the recipient of a large drop in short interest in the month of June. As of June 30th, there was short interest totalling 15,500 shares, a drop of 44.2% from the June 15th total of 27,800 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average trading volume of 83,900 shares, the short-interest ratio is currently 0.2 days.July 12, 2024 | marketbeat.comConnect Biopharma Holdings Limited (NASDAQ:CNTB) Short Interest UpdateConnect Biopharma Holdings Limited (NASDAQ:CNTB - Get Free Report) saw a large decrease in short interest during the month of June. As of June 15th, there was short interest totalling 27,800 shares, a decrease of 21.5% from the May 31st total of 35,400 shares. Based on an average daily volume of 114,100 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.1% of the company's stock are short sold.July 1, 2024 | marketbeat.comConnect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics ForumJuly 1, 2024 | globenewswire.comConnect Biopharma Holdings Limited (NASDAQ:CNTB) Short Interest Down 34.6% in MayConnect Biopharma Holdings Limited (NASDAQ:CNTB - Get Free Report) was the recipient of a large drop in short interest during the month of May. As of May 31st, there was short interest totalling 35,400 shares, a drop of 34.6% from the May 15th total of 54,100 shares. Approximately 0.1% of the company's shares are sold short. Based on an average daily volume of 118,800 shares, the days-to-cover ratio is presently 0.3 days.June 16, 2024 | marketbeat.comConnect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 12, 2024 | globenewswire.comConnect Biopharma Announces New Leadership and Chair of the Board of DirectorsJune 12, 2024 | globenewswire.comConnect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe AsthmaMay 22, 2024 | globenewswire.comConnect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe AsthmaMay 7, 2024 | globenewswire.comConnect Biopharma Holdings Limited (CNTB)April 26, 2024 | finance.yahoo.comBML Capital Management LLC Makes New $2.43 Million Investment in Connect Biopharma Holdings Limited (NASDAQ:CNTB)BML Capital Management LLC acquired a new position in Connect Biopharma Holdings Limited (NASDAQ:CNTB - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 2,061,438 shares of the company's stoApril 24, 2024 | marketbeat.comHC Wainwright Analysts Lift Earnings Estimates for Connect Biopharma Holdings Limited (NASDAQ:CNTB)Connect Biopharma Holdings Limited (NASDAQ:CNTB - Free Report) - Equities researchers at HC Wainwright boosted their FY2024 earnings estimates for shares of Connect Biopharma in a note issued to investors on Wednesday, April 17th. HC Wainwright analyst E. Bodnar now anticipates that the company wApril 19, 2024 | marketbeat.comConnect Biopharma (NASDAQ:CNTB) Given New $8.00 Price Target at HC WainwrightHC Wainwright raised their price target on Connect Biopharma from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Wednesday.April 17, 2024 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Connect Biopharma Holdings (CNTB)April 17, 2024 | markets.businessinsider.com Get Connect Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter. Email Address CNTB Media Mentions By Week CNTB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CNTB News Sentiment▼0.430.87▲Average Medical News Sentiment CNTB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CNTB Articles This Week▼30▲CNTB Articles Average Week Get Connect Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MOLN News Today RAPT News Today DERM News Today FDMT News Today VYGR News Today CYBN News Today PBYI News Today LFVN News Today ESPR News Today SLN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CNTB) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Connect Biopharma Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Connect Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CNTB Stock Free CNTB Stock Alerts